UA's Center for Innovation has opened its third incubator in Oro Valley with a focus on nurturing local bioscience businesses.

Celgene and Bristol-Myers Squibb have scored exits as the oncology drug developer priced an upsized offering above its range.

The Chernin Group-backed series D round valued the medical test provider at $1.3bn while pushing its total funding past $250m.

The gene-editing drug developer has completed its first publicly announced round to advance UC and ETH Zürich research.

Novo Nordisk Foundation's BioInnovation Institute has funded seven new projects with debt financing and grants to progress research in areas like male infertility and stem cell therapies.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

JD.com's medical products spinoff has gone public in Hong Kong's largest initial public offering this year, valuing it at close to $29bn.

Rock Springs has led a round that will drive R&D and recruitment at AI drug design company Genesis Therapeutics, which emerged out of Stanford.

Johns Hopkins and Pitt-linked digital pathology platform Proscia has increased its funding total to $35m with a series B round involving Hitachi Ventures.

Digital pathology technology developer Proscia has boosted its total funding to $35m with a series B round featuring Hitachi Ventures.